Effect and Molecular Mechanism of MiR-181a-5p on the Proliferation and Invasion of Papillary Thyroid Cancer Cells

Junwen Hao; Weijun Huang; Songming Li

Authors

Junwen Hao Department of Breast and Thyroid Surgery, Panyu Central Hospital Affiliated to Guangzhou Medical University, 511400 Guangzhou, Guangdong, China Author
Weijun Huang Department of Breast and Thyroid Surgery, Panyu Central Hospital Affiliated to Guangzhou Medical University, 511400 Guangzhou, Guangdong, China Author
Songming Li Department of Breast and Thyroid Surgery, Panyu Central Hospital Affiliated to Guangzhou Medical University, 511400 Guangzhou, Guangdong, China Author

Keywords:

Papillary thyroid cancer, MiR-181a-5p, Thyrotropin receptor, proliferation, invasion

Abstract

Objective: To investigate the effect and regulation mechanism of miR-181a-5p on papillary thyroid carcinoma (PTC) cells. Methods: The expressions of miR-181a-5p and thyrotropin receptor (TSHR) in PTC tissues, and the targeting relationship between these two genes were analyzed using bioinformatics tools, and their targeting relationship was verified by dual-luciferase reporter assay. After TPC-1 cells were transfected with miR-181a-5p inhibitor and shTSHR, the expression levels of miR-181a-5p, TSHR, E-cadherin, N-cadherin and Vimentin were detected by quantitative reverse transcription polymerase chain reaction or Western blot assay. The effects of miR-181a-5p and TSHR on the viability and invasion of TPC-1 cells were detected by MTT and Transwell assay. Results: The expression of miR-181a-5p was upregulated in PTC tissues and cells (p < 0.001), and the expression of TSHR was lowered in PC tissues. MiR-181a-5p could directly target TSHR. Downregulation of miR-181a-5p inhibited viability and invasion, and the expressions of N-cadherin and Vimentin (p < 0.01), but promoted the expression of E-cadherin in TPC-1 cells (p < 0.001). TSHR knockdown produced the opposite results (p < 0.01), and partially reversed the effect of miR-181a-5p downregulation on TPC-1 cells (p < 0.01). Conversely, down-regulation of miR-181a-5p could offset the effect of TSHR knockdown (p < 0.05). Conclusion: Downregulation of miR-181a-5p suppressed the malignant progression of PTC cells by promoting TSHR expression.

References

Grimm D. Recent Advances in Thyroid Cancer Research. International Journal of Molecular Sciences 2022; 23(9): 4631.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2021; 71(3): 209-249.

Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 2021; 11(13): 6251-6277.

Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review. Advances in Therapy 2020; 37(7): 3112-3128.

Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology: Mechanisms of Disease 2018; 13: 395-412.

Zhu Y, Peng X, Zhou Q, et al. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death & Disease 2022; 13(4): 358.

Lu TX, Rothenberg ME. MicroRNA. Journal of Allergy and Clinical Immunology 2018; 141(4): 1202-1207.

Hussen BM, Hidayat HJ, Salihi A, et al. MicroRNA: A signature for cancer progression. Biomedicine & Pharmacotherapy 2021; 138: 111528.

Galuppini F, Censi S, Merante Boschin I, et al. Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology 2022; 13: 834075.

Gierlikowski W, Broniarek K, Cheda Ł, et al. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma. International Journal of Molecular Sciences 2021; 22(11): 6067.

Mi Y, Zhang D, Jiang W, et al. miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Letters 2017; 389: 11-22.

Ali Syeda Z, Langden SSS, Munkhzul C, et al. Regulatory Mechanism of MicroRNA Expression in Cancer. International Journal of Molecular Sciences 2020; 21(5): 1723.

Szkudlinski MW, Fremont V, Ronin C, et al. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiological Reviews 2002; 82(2): 473-502.

Liu TR, Su X, Qiu WS, et al. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma. European Review for Medical and Pharmacological Sciences 2016; 20(17): 3582-3591.

Liu T, Men Q, Su X, et al. Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer. Oncology Letters 2017; 14(6): 7506-7512.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-408.

Ulisse S, Baldini E, Lauro A, et al. Papillary Thyroid Cancer Prognosis: An Evolving Field. Cancers 2021; 13(21): 5567.

Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. The Lancet Diabetes & Endocrinology 2014; 2(5): 356-358.

Zhai Z, Mu T, Zhao L, et al. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway. Bioengineered 2022; 13(1): 83-95.

Hu W, Yan F, Ru Y, et al. MIIP inhibits EMT and cell invasion in prostate cancer through miR-181a/b-5p-KLF17 axis. American Journal of Cancer Research 2020; 10(2): 630-647.

Yang M, Zhai X, Ge T, et al. miR-181a-5p Promotes Proliferation and Invasion and Inhibits Apoptosis of Cervical Cancer Cells via Regulating Inositol Polyphosphate-5-Phosphatase A (INPP5A). Oncology Research 2018; 26(5): 703-712.

Chen G, Shen ZL, Wang L, et al. Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pacific Journal of Cancer Prevention 2013; 14(6): 3871-3875.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology 2019; 20(2): 69-84.

Suresh Babu V, Bisht A, Mallipatna A, et al. Enhanced Epithelial-to-Mesenchymal Transition and Chemoresistance in Advanced Retinoblastoma Tumors Is Driven by miR-181a. Cancers 2022; 14(20): 5124.

Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Frontiers of Medicine 2018; 12(4): 361-373.

Loh CY, Chai JY, Tang TF, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019; 8(10): 1118.

Ridge KM, Eriksson JE, Pekny M, et al. Roles of vimentin in health and disease. Genes & Development 2022; 36(7-8): 391-407.

Zhang C, Bo C, Guo L, et al. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis. World Journal of Surgical Oncology 2019; 17(1): 221.

Titus S, Neumann S, Zheng W, et al. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. Journal of Biomolecular Screening 2008; 13(2): 120-127.

Liu J, Liu Y, Lin Y, et al. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinology and Metabolism 2019; 34(3): 215-225.

Zhang J, Zhao A, Jia X, et al. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer. International Journal of Molecular Sciences 2022; 23(18): 10709.

Klimaitė R, Kazokaitė M, Kondrotienė A, et al. The Role of TSHR, PTEN and RASSF1A Promoters' Methylation Status for Non-Invasive Detection of Papillary Thyroid Carcinoma. Journal of Clinical Medicine 2022; 11(16): 4917.

Li H, Zhou X, Wang G, et al. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism 2022; 107(4): 1110-1126.

Alsina J, Alsina R, Gulec S. A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. Molecular Imaging and Radionuclide Therapy 2017; 26(Suppl 1): 102-117.